CTSD, EGFR, and CCND1 gene expression did not show any significant differences in patients with breast cancer subtypes such as Basal, Her2, Luminal A, and Luminal B. However, BCL2 showed a significant (p < 0.05) decreased risk in Luminal B patients according to the Cox proportional hazard model (survival analysis estimated using TIMER2.0). This evidence concerns the gene BCL2 and breast carcinoma.